hVIVO

FDA Openness And Pandemic Preparedness Will Fuel Expansion

AnalystHighTarget

Not Invested

Consensus Narrative from 8 Analysts

Published

14 Jul 25

Updated

08 Aug 25

AnalystHighTarget's Fair Value

UK£0.37

70.7% undervalued

08 Aug

UK£0.11

-62.8%

8.5%

Author's Valuation

UK£0.4

70.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

UK£0.4

70.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.90%

Life Sciences revenue growth rate

0.33%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.58%

Calculation

UK£10.03m

Earnings '28

31.24x

PE Ratio '28

UK£313.42m

Market Cap '28

UK£313.42m

Market Cap '28

680.37m

No. shares '28

UK£0.46

Share Price '28

UK£0.46 Share Price '28

Discounted to 2025 @ 7.60% p.a.

UK£0.37

Fair Value '25